Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot randomized open-label trial of hydroxychloroquine, azithromycin, and tocilizumab for COVID-19
2020-001442-19Phase 2Completed
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: In-hospital mortality or need for mechanical ventilation in the Intensive Care Unit. Started Apr 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001442-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001442-19.